胶质瘤的免疫治疗进展
|
摘要
胶质瘤作为一种颅内常见肿瘤,在过去的一个世纪,其临床治疗方面几乎没有显著的进展.免疫疗法作为一种新兴的治疗模式备受瞩目,关于胶质瘤免疫治疗的效果也有很多争议.本文就胶质瘤临床免疫治疗的现状、现阶段所存在的缺陷,以及其未来的潜力作一综述.
Glioma is a common intracranial tumor. In the past century,there is little progress in the clinical treatment of gliomas. Immunotherapy,as a new treatment model,has attracted much attention. The efficacy of immunotherapy for glioma is also controversial. In this article,we will discuss the current status of clinical immunotherapy for glioma,the shortcomings of the present stage,and its future potentiality.
Glioma is a common intracranial tumor. In the past century,there is little progress in the clinical treatment of gliomas. Immunotherapy,as a new treatment model,has attracted much attention. The efficacy of immunotherapy for glioma is also controversial. In this article,we will discuss the current status of clinical immunotherapy for glioma,the shortcomings of the present stage,and its future potentiality.
引文
[1]王文雯.卡莫司汀植入剂治疗脑胶质瘤的研究进展[J].中国肿瘤临床与康复,2015(2):254-256.
[2]Punsoni M,Donahue JE,Elinzano HD,et al.Updates in molecular pathology of central nervous system gliomas in adults[J].R I Med J,2015,98(11):17-19.
[3]Lasocki A,Tsui A,Tacey MA,et al.MRI Grading versus histology:Predicting survival of world health organization grade II-IV astrocytomas[J].AJNR Am J Neuroradiol,2015,36(1):77-83.
[4]Oliveira-Nunes MC,Assad Kahn S,de Oliveira Barbeitas AL,et al.The availability of the embryonic TGF-βprotein Nodal is dynamically regulated during glioblastomamultiforme tumorigenesis[J].Cancer Cell Int,2016,16(1):1-10.
[5]Stupp R,Mason WP,van den Bent MJ,et al.Radiotherapy plus concomitant and adjuvanttemozolomide for glioblastoma[J].N Engl J Med,2005,352:987-996.
[6]Zhao J,Zhang L,Dong X,et al.High expression of vimentin is associated with progression and a poor outcome in glioblastoma[J].Appl Immunohistochem Mol Morphol,2016.
[7]Chen L,Li X,Liu L,et al.Erastin sensitizes glioblastoma cells to temozolomide by restraining x CT and cystathionine-γ-lyase function[J].Oncol Rep,2015,33(3):1465-1474.
[8]Aguilar-Cordova CE.Methods of cytotoxic gene therapy to treat tumors:,US20150086541[P].2015.
[9]Zhang X,Rao A,Sette P,et al.IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression[J].Neuro-oncology,2016,18(10):1402-1412.
[10]唐重阳,葛海涛,林志国,等.失控的CD70在脑胶质瘤的发生与治疗中的潜在作用[J].现代生物医学进展,2016,16(7):1363-1365.
[11]Mittelbronn M,Platten M,Zeiner P,et al.Macrophage migration inhibitory factor(MIF)expression in human malignant gliomas contributes to immune escape and tumour progression[J].Acta Neuropathol,2011,122(3):353-365.
[12]Li L,Goedegebuure P,Mardis ER,et al.Cancer genome sequencing and its implications for personalized cancer vaccines[J].Cancers,2011,3(4):4191-4211.
[13]Wu AA,Drake V,Huang HS,et al.Reprogramming the tumor microenvironment:tumor-induced immunosuppressive factors paralyz T cells[J].Oncoimmunology,2015,4(7):e1016700.
[14]霍毅,陈功金,申彦彦,等.组蛋白H2A去泛素化酶MYSM1抑制骨髓来源树突状细胞的抗原提呈功能及炎性细胞因子的分泌[J].细胞与分子免疫学杂志,2016,32(12):1654-1657.
[15]陈新.肝癌小鼠来源的调节性T细胞对肿瘤免疫抑制作用的研究[D].温州:温州医学院,2013.
[16]Fecci PE,Sampson JH.Clinical immunotherapy for brain tumors[J].Neuroimaging Clin N Am,2002,12(4):641-664.
[17]Reardon DA,Wucherpfennig KW,Freeman G,et al.An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma[J].Expert Rev Vaccines,2013,12(6):597-615.
[18]Favoino E,Prete M,Marzullo A,et al.CD20-mimotope peptide active immunotherapy in systemic lupus erythematosus and a reappraisalof vaccination strategies in rheumatic diseases[J].Clin Rev Allergy Immunol,2017,52(2):217-233.
[19]Truxova I,Fucikova J,Spisek R,et al.Method for preparing dendritic cells to be used as antigen-presenting cells in immunotherapy:EP2829600[P].2015.
[20]李国亮,王选重,田沁森,等.脑胶质瘤综合治疗新进展[J].转化医学电子杂志,2017,4(7):16-20.
[21]Quintana FJ,Yeste A,Mascanfroni I D.Role and therapeutic value of dendritic cells in central nervous system autoimmunity[J].Cell Death Differ,2015,22(2):215-24.
[22]Ramirez O,Garza KM.Leptin deficiency in vivo enhances the ability of splenic dendritic cells to activate T cells[J].Int Immunol,2014,26(11):627-636.
[23]Tano T,Okamoto M,Goda H,et al.Abstract 4722:Enhancement of the T cell-stimulating ability of dendritic cells by 5-FU via regulationof the expression of ligands for programed cell death 1[J].Cancer Res,2013,73(8):4722-4722.
[24]徐杰,陆华,吴卫江,等.人脑胶质瘤树突状细胞疫苗的临床应用[J].江苏医药,2012(10):1193-1196.
[25]肖宗宇,陈晓娟,杨艺,等.肿瘤干细胞样细胞RNA致敏树突状细胞治疗大鼠9L脑肿瘤[J].北京大学学报(医学版),2015,47(4):661-666.
[26]张芸,纪惜銮,罗朝霞,等.恶性胶质瘤相关抗原表位肽激活的树突状细胞致敏的细胞毒性T淋巴细胞靶向治疗恶性胶质瘤的实验研究[J].中国临床药理学杂志,2017,33(5):448-451.
[27]王莹.IL-13Ra2抗原肽致敏树突状细胞对人脑胶质瘤及其肿瘤干细胞的杀伤效应研究[D].武汉:华中科技大学,2013.
[28]卜宁,吴海琴,孙秉中.树突状细胞负载的exosome疫苗抗胶质瘤的实验研究[J].现代肿瘤医学,2010,18(9):1684-1687.
[29]涂艳阳,徐小珊,张永生,等.胶质瘤中甲基化沉默肿瘤抑制因子的研究进展[J].转化医学电子杂志,2016,3(2):1-7.
[30]Phuphanich S,Wheeler CJ,Rudnick JD,et al.Phase I trial of amulti-epitope-pulsed dendritic cell vaccine for patients with newlydiagnosed glioblastoma[J].Cancer Immunol Immunother,2013,62(1):125-135.
[31]崔建东,彭清云,李涛,等.放化疗联合DC-CIK治疗脑胶质瘤复发40例的临床观察[J].现代生物医学进展,2013,13(20):3860-3862,3991.
[32]Zhu Y,Zheng Y,Mei L,et al.Enhanced immunotherapeutic effect of modified HPV16 E7-pulsed dendritic cell vaccine by an adenoshRNA-SOCS1 virus[J].Int J Oncol,2013,43(4):1151-1159.
[33]Ribas A,Comin-Anduix B,Chmielowski B,et al.Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma[J].Clin Cancer Res,2009,15(19):6267-6276.
[34]Berntsen A,Trepiakas R,Wenandy L,et al.Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma:aclinical phase1/2 trail[J].J Immunother,2008,31(8):771-780.
[35]Ishikawa E,Tsuboi K,Yamamoto T,et al.Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients[J].Cancer Sci,2007,98(8):1226-1233.
[36]Okada H,Lieberman FS,Walter KA,et al.Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas[J].J Transl Med,2007,5:67.
[37]Steiner HH,Bonsanto MM,Beckhove P,et al.Antitumor vaccination of patients with glioblastoma multiforme:a pilot study to assess feasibility,safety,and clinical benefit[J].J Clin Oncol,2004,22(21):4272-4281.
[38]Ahn BJ,Pollack IF,Okada H.Immune-checkpoint blockade and active immunotherapy for glioma[J].Cancers(Basel),2013,5(4):1379-1412.
[39]Ohno M,Natsume A,Ichiro Iwami K,et al.Retrovirally engineered T-cell-based immunotherapy targeting typeⅢvariant epidermal growth factor receptor,a glioma-associated antigen[J].Cancer Sci,2010,101(12):2518-2524.
[40]Hatiboglu MA,Wei J,Wu AS,et al.Immune therapeutic targeting of glioma cancer stem cells[J].Target Oncol,2010,5(3):217-227.
[41]Izumoto S,Tsuboi A,Oka Y,et al.Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme[J].J Neurosurg.2008,108(5):963-971.
[42]Rosenberg SA,Yang JC,Restifo NP.Cancer immunotherapy:moving beyond current vaccines[J].Nat Med,2004,10(9):909-915.
[43]Sampson JH,Heimberger AB,Archer GE,et al.Immunologic escape after prolonged progression-free survival with epidermalgrowth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma[J].J Clin Oncol,2010,28(31):4722-4729.
[44]Zhou DG,Liang Z,Fan ZY,et al.Effects of passive immunization against peptide tyrosine tyrosine on the growth performance and endocrine hormone levels in blood serum of rats[J].Adv JFood Sci Technol,2013,5(2):99-105.
[45]Harris M.Monoclonal antibodies as therapeutic agents for cancer[J].Lancet Oncol,2004,5(5):292-302.
[46]Wikstrand CJ,Hale LP,Batra SK,et al.Monoclonal antibodies against EGFRvⅢare tumor specific and react with breast and lung carcinomas and malignant gliomas[J].Cancer Res,1995,55(14):3140-3148.
[47]Sampson JH,Crotty LE,Lee S,et al.Unarmed,tumor-specific monoclonal antibody effectively treats brain tumors[J].Proc Natl Acad Sci USA,2000,97(13):7503-7508.
[48]Perera RM,Narita Y,Furnari FB,et al.Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypicalepidermal growth factor receptor-specific antibody generates enhanced antitumor activity[J].Clin Cancer Res,2005,11(17):6390-6399.
[49]Zalutsky MR,Reardon DA,Akabani G,et al.Clinical experience withα-particle-emitting 211At:treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6[J].J Nucl Med,2008,49(1):30-38.
[50]Galluzzi L,Vacchelli E,Bravo-San Pedro JM,et al.Classification of current anticancer immunotherapies[J].Oncotarget,2014,5(24):12472-12508.
[51]Mineharu Y,Muhammad AK,Yagiz K,et al.Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-kappa B signaling improves the efficacy of immunotherapy in a brain cancer model[J].Neurotherapeutics,2012,9(4):827-843.
[52]Fritzell S,Eberstl S,Sanden E,et al.IFNγin combination with IL-7 enhances immunotherapy in two rat glioma models[J].J Neuroimmunol,2013,25 8(1-2):91-95.
[53]Santegoets SJ,Turksma AW,Powell Jr DJ,et al.IL-21 in cancer immunotherapy:At the right place at the right time[J].Oncoimmunology,2013,2(6):e24522.
[54]Hau P,Jachimczak P,Schlingensiepen R,et al.Inhibition of TGFbeta2 with AP 12009 in recurrent malignant gliomas:from preclinicalto phaseⅠ/Ⅱstudies[J].Oligonucleotides,2007,17(2):201-212.
[55]涂艳阳,祁婧,张永生.胶质瘤中分子标记物的应用进展[J].转化医学电子杂志,2016,3(7):1-5.
[56]Christofides A,Kosmopoulos M,Piperi C.Pathophysiological mechanisms regulated by cytokines in gliomas[J].Cytokine,2015,71(2):377-384.
[2]Punsoni M,Donahue JE,Elinzano HD,et al.Updates in molecular pathology of central nervous system gliomas in adults[J].R I Med J,2015,98(11):17-19.
[3]Lasocki A,Tsui A,Tacey MA,et al.MRI Grading versus histology:Predicting survival of world health organization grade II-IV astrocytomas[J].AJNR Am J Neuroradiol,2015,36(1):77-83.
[4]Oliveira-Nunes MC,Assad Kahn S,de Oliveira Barbeitas AL,et al.The availability of the embryonic TGF-βprotein Nodal is dynamically regulated during glioblastomamultiforme tumorigenesis[J].Cancer Cell Int,2016,16(1):1-10.
[5]Stupp R,Mason WP,van den Bent MJ,et al.Radiotherapy plus concomitant and adjuvanttemozolomide for glioblastoma[J].N Engl J Med,2005,352:987-996.
[6]Zhao J,Zhang L,Dong X,et al.High expression of vimentin is associated with progression and a poor outcome in glioblastoma[J].Appl Immunohistochem Mol Morphol,2016.
[7]Chen L,Li X,Liu L,et al.Erastin sensitizes glioblastoma cells to temozolomide by restraining x CT and cystathionine-γ-lyase function[J].Oncol Rep,2015,33(3):1465-1474.
[8]Aguilar-Cordova CE.Methods of cytotoxic gene therapy to treat tumors:,US20150086541[P].2015.
[9]Zhang X,Rao A,Sette P,et al.IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression[J].Neuro-oncology,2016,18(10):1402-1412.
[10]唐重阳,葛海涛,林志国,等.失控的CD70在脑胶质瘤的发生与治疗中的潜在作用[J].现代生物医学进展,2016,16(7):1363-1365.
[11]Mittelbronn M,Platten M,Zeiner P,et al.Macrophage migration inhibitory factor(MIF)expression in human malignant gliomas contributes to immune escape and tumour progression[J].Acta Neuropathol,2011,122(3):353-365.
[12]Li L,Goedegebuure P,Mardis ER,et al.Cancer genome sequencing and its implications for personalized cancer vaccines[J].Cancers,2011,3(4):4191-4211.
[13]Wu AA,Drake V,Huang HS,et al.Reprogramming the tumor microenvironment:tumor-induced immunosuppressive factors paralyz T cells[J].Oncoimmunology,2015,4(7):e1016700.
[14]霍毅,陈功金,申彦彦,等.组蛋白H2A去泛素化酶MYSM1抑制骨髓来源树突状细胞的抗原提呈功能及炎性细胞因子的分泌[J].细胞与分子免疫学杂志,2016,32(12):1654-1657.
[15]陈新.肝癌小鼠来源的调节性T细胞对肿瘤免疫抑制作用的研究[D].温州:温州医学院,2013.
[16]Fecci PE,Sampson JH.Clinical immunotherapy for brain tumors[J].Neuroimaging Clin N Am,2002,12(4):641-664.
[17]Reardon DA,Wucherpfennig KW,Freeman G,et al.An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma[J].Expert Rev Vaccines,2013,12(6):597-615.
[18]Favoino E,Prete M,Marzullo A,et al.CD20-mimotope peptide active immunotherapy in systemic lupus erythematosus and a reappraisalof vaccination strategies in rheumatic diseases[J].Clin Rev Allergy Immunol,2017,52(2):217-233.
[19]Truxova I,Fucikova J,Spisek R,et al.Method for preparing dendritic cells to be used as antigen-presenting cells in immunotherapy:EP2829600[P].2015.
[20]李国亮,王选重,田沁森,等.脑胶质瘤综合治疗新进展[J].转化医学电子杂志,2017,4(7):16-20.
[21]Quintana FJ,Yeste A,Mascanfroni I D.Role and therapeutic value of dendritic cells in central nervous system autoimmunity[J].Cell Death Differ,2015,22(2):215-24.
[22]Ramirez O,Garza KM.Leptin deficiency in vivo enhances the ability of splenic dendritic cells to activate T cells[J].Int Immunol,2014,26(11):627-636.
[23]Tano T,Okamoto M,Goda H,et al.Abstract 4722:Enhancement of the T cell-stimulating ability of dendritic cells by 5-FU via regulationof the expression of ligands for programed cell death 1[J].Cancer Res,2013,73(8):4722-4722.
[24]徐杰,陆华,吴卫江,等.人脑胶质瘤树突状细胞疫苗的临床应用[J].江苏医药,2012(10):1193-1196.
[25]肖宗宇,陈晓娟,杨艺,等.肿瘤干细胞样细胞RNA致敏树突状细胞治疗大鼠9L脑肿瘤[J].北京大学学报(医学版),2015,47(4):661-666.
[26]张芸,纪惜銮,罗朝霞,等.恶性胶质瘤相关抗原表位肽激活的树突状细胞致敏的细胞毒性T淋巴细胞靶向治疗恶性胶质瘤的实验研究[J].中国临床药理学杂志,2017,33(5):448-451.
[27]王莹.IL-13Ra2抗原肽致敏树突状细胞对人脑胶质瘤及其肿瘤干细胞的杀伤效应研究[D].武汉:华中科技大学,2013.
[28]卜宁,吴海琴,孙秉中.树突状细胞负载的exosome疫苗抗胶质瘤的实验研究[J].现代肿瘤医学,2010,18(9):1684-1687.
[29]涂艳阳,徐小珊,张永生,等.胶质瘤中甲基化沉默肿瘤抑制因子的研究进展[J].转化医学电子杂志,2016,3(2):1-7.
[30]Phuphanich S,Wheeler CJ,Rudnick JD,et al.Phase I trial of amulti-epitope-pulsed dendritic cell vaccine for patients with newlydiagnosed glioblastoma[J].Cancer Immunol Immunother,2013,62(1):125-135.
[31]崔建东,彭清云,李涛,等.放化疗联合DC-CIK治疗脑胶质瘤复发40例的临床观察[J].现代生物医学进展,2013,13(20):3860-3862,3991.
[32]Zhu Y,Zheng Y,Mei L,et al.Enhanced immunotherapeutic effect of modified HPV16 E7-pulsed dendritic cell vaccine by an adenoshRNA-SOCS1 virus[J].Int J Oncol,2013,43(4):1151-1159.
[33]Ribas A,Comin-Anduix B,Chmielowski B,et al.Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma[J].Clin Cancer Res,2009,15(19):6267-6276.
[34]Berntsen A,Trepiakas R,Wenandy L,et al.Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma:aclinical phase1/2 trail[J].J Immunother,2008,31(8):771-780.
[35]Ishikawa E,Tsuboi K,Yamamoto T,et al.Clinical trial of autologous formalin-fixed tumor vaccine for glioblastoma multiforme patients[J].Cancer Sci,2007,98(8):1226-1233.
[36]Okada H,Lieberman FS,Walter KA,et al.Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas[J].J Transl Med,2007,5:67.
[37]Steiner HH,Bonsanto MM,Beckhove P,et al.Antitumor vaccination of patients with glioblastoma multiforme:a pilot study to assess feasibility,safety,and clinical benefit[J].J Clin Oncol,2004,22(21):4272-4281.
[38]Ahn BJ,Pollack IF,Okada H.Immune-checkpoint blockade and active immunotherapy for glioma[J].Cancers(Basel),2013,5(4):1379-1412.
[39]Ohno M,Natsume A,Ichiro Iwami K,et al.Retrovirally engineered T-cell-based immunotherapy targeting typeⅢvariant epidermal growth factor receptor,a glioma-associated antigen[J].Cancer Sci,2010,101(12):2518-2524.
[40]Hatiboglu MA,Wei J,Wu AS,et al.Immune therapeutic targeting of glioma cancer stem cells[J].Target Oncol,2010,5(3):217-227.
[41]Izumoto S,Tsuboi A,Oka Y,et al.Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme[J].J Neurosurg.2008,108(5):963-971.
[42]Rosenberg SA,Yang JC,Restifo NP.Cancer immunotherapy:moving beyond current vaccines[J].Nat Med,2004,10(9):909-915.
[43]Sampson JH,Heimberger AB,Archer GE,et al.Immunologic escape after prolonged progression-free survival with epidermalgrowth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma[J].J Clin Oncol,2010,28(31):4722-4729.
[44]Zhou DG,Liang Z,Fan ZY,et al.Effects of passive immunization against peptide tyrosine tyrosine on the growth performance and endocrine hormone levels in blood serum of rats[J].Adv JFood Sci Technol,2013,5(2):99-105.
[45]Harris M.Monoclonal antibodies as therapeutic agents for cancer[J].Lancet Oncol,2004,5(5):292-302.
[46]Wikstrand CJ,Hale LP,Batra SK,et al.Monoclonal antibodies against EGFRvⅢare tumor specific and react with breast and lung carcinomas and malignant gliomas[J].Cancer Res,1995,55(14):3140-3148.
[47]Sampson JH,Crotty LE,Lee S,et al.Unarmed,tumor-specific monoclonal antibody effectively treats brain tumors[J].Proc Natl Acad Sci USA,2000,97(13):7503-7508.
[48]Perera RM,Narita Y,Furnari FB,et al.Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypicalepidermal growth factor receptor-specific antibody generates enhanced antitumor activity[J].Clin Cancer Res,2005,11(17):6390-6399.
[49]Zalutsky MR,Reardon DA,Akabani G,et al.Clinical experience withα-particle-emitting 211At:treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6[J].J Nucl Med,2008,49(1):30-38.
[50]Galluzzi L,Vacchelli E,Bravo-San Pedro JM,et al.Classification of current anticancer immunotherapies[J].Oncotarget,2014,5(24):12472-12508.
[51]Mineharu Y,Muhammad AK,Yagiz K,et al.Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-kappa B signaling improves the efficacy of immunotherapy in a brain cancer model[J].Neurotherapeutics,2012,9(4):827-843.
[52]Fritzell S,Eberstl S,Sanden E,et al.IFNγin combination with IL-7 enhances immunotherapy in two rat glioma models[J].J Neuroimmunol,2013,25 8(1-2):91-95.
[53]Santegoets SJ,Turksma AW,Powell Jr DJ,et al.IL-21 in cancer immunotherapy:At the right place at the right time[J].Oncoimmunology,2013,2(6):e24522.
[54]Hau P,Jachimczak P,Schlingensiepen R,et al.Inhibition of TGFbeta2 with AP 12009 in recurrent malignant gliomas:from preclinicalto phaseⅠ/Ⅱstudies[J].Oligonucleotides,2007,17(2):201-212.
[55]涂艳阳,祁婧,张永生.胶质瘤中分子标记物的应用进展[J].转化医学电子杂志,2016,3(7):1-5.
[56]Christofides A,Kosmopoulos M,Piperi C.Pathophysiological mechanisms regulated by cytokines in gliomas[J].Cytokine,2015,71(2):377-384.